Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q3 2024 (September 30)9holders −2
2new positions
4sold out
$0.04avg. 13F price*
At the end of Q3 2024, 9 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, down 2 from Q2 2024. 2 opened new positions and 4 sold out. The largest holders were HB Wealth Management, LLC ($11K), Morgan Stanley ($5K) and Yakira Capital Management, Inc. ($4K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $11K |
| Exits | 4 | $37K |
All 13F filers, Q2 2024 → Q3 2024: 310,400 shares bought and 788,987 shares sold, net −478,587 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| HB Wealth Management, LLC | — | New | 310,000 | $11K |
| Morgan Stanley | — | No change | 146,439 | $5K |
| Yakira Capital Management, Inc. | — | No change | 108,485 | $4K |
| Walleye Capital LLC | — | No change | 23,258 | $837 |
| Wolverine Asset Management LLC | — | Add +1.3% | 15,519 | $558 |
| Walleye Trading LLC | — | No change | 15,505 | $558 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $39 |
| Clear Street LLC | — | New | 200 | $7 |
| Tower Research Capital LLC (TRC) | — | No change | 48 | $2 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.